SynthesisBMC public health2025
Prevalence of HIV drug resistance among patients experiencing first-line treatment failure in Ethiopia: a systematic review and meta-analysis.
Synthesis in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Virologic and Immunological Failure and Associated Factors Among Adults Living With HIV on HAART at Jimma Medical Center, Southwest Ethiopia.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe emergence of human immunodefiency virus (HIV) drug resistance presents a substantial challenge. Alternatives for effective treatment regimens are limited, and treatment strategies are complicated. Although a number of primary studies have been performed on HIV drug resistance in Ethiopia, individual study often lacks the statistical strength to draw conclusion. Therefore, the objective of this systematic review and meta-analysis was to estimate the pooled prevalence of HIV1 drug resistance among patients experiencing first-line treatment failure in Ethiopia.
methodsPrimary studies were searched from PubMed, SCOPUS, Embase, Google Scholar and online libraries. Studies identified through the search strategies were screened by titles and abstracts. Included studies were evaluated for risk of bias using the Joanna Briggs Institute (JBI) checklist. Data were extracted, and the pooled prevalence of HIV drug resistance was computed using STATA 17 software. Subgroup analysis and meta-regression were performed to identify heterogeneity. Publication bias was checked visually and statistically. Narrative synthesis was performed to describe study characteristics and findings; and forest plots were used to visually represent effect sizes and confidence intervals from individual studies to present and synthesize the results.
resultsA total of 10 studies with 1233 participants were included. The pooled prevalence rate of HIV drug resistance in patients with first line treatment failure was 73% (95% CI: 67-78%, I
conclusionsThe prevalence rate of HIV drug resistance in Ethiopia is high. This alarms health care workers, programmers and decision makers to consider ways of controlling the emergence of HIV drug resistance and the spread of drug-resistant strains. Timely monitoring of treatment failures, HIV drug resistance testing and switching on appropriate regimen classes are crucial for better treatment outcomes. There was high HIV drug resistance among children but with a high heterogeneity indicating the need for more primary studies. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42024533975.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.